Cargando…

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

The purpose of this study was to evaluate by a retrospective analysis of 53 patients the efficacy of chemotherapy combining etoposide and cisplatin in the treatment of neuroendocrine tumours. The regimen was a combination of etoposide 100 mg m(–2) day(–1) for 3 days and cisplatin 100 mg m(–2) on day...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitry, E, Baudin, E, Ducreux, M, Sabourin, J-C, Rufié, P, Aparicio, T, Lasser, P, Elias, D, Duvillard, P, Schlumberger, M, Rougier, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362979/ https://www.ncbi.nlm.nih.gov/pubmed/10604732 http://dx.doi.org/10.1038/sj.bjc.6690325

Ejemplares similares

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
por: Baudin, E., et al.
Publicado: (1998)

Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Réseau Comète INSERM.
por: Bonacci, R., et al.
Publicado: (1998)

Cancer of the rectum
por: Bécouarn, Y, et al.
Publicado: (2001)

Absence of somatic alterations of the EB1 gene adenomatous polyposis coli-associated protein in human sporadic colorectal cancers.
por: Jaïs, P., et al.
Publicado: (1998)

A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma
por: Horwich, A, et al.
Publicado: (2000)

Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604)
por: Cafferty, Fay H., et al.
Publicado: (2020)

Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours
por: Fleischhack, G, et al.
Publicado: (2001)

Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma
por: Michelagnoli, M P, et al.
Publicado: (1999)

Extensive molecular screening for hereditary non-polyposis colorectal cancer
por: Dieumegard, B, et al.
Publicado: (2000)

Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study
por: Zhang, Panpan, et al.
Publicado: (2020)

Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study
por: Scinto, A F, et al.
Publicado: (1999)

Carcinoma of the colon
por: Adenis, A, et al.
Publicado: (2001)

A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours
por: Bernini, G P, et al.
Publicado: (2001)

Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease
por: Dobson, L S, et al.
Publicado: (2000)

Chromogranin A and the α -subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma
por: Guignat, L, et al.
Publicado: (2001)

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma
por: Yoon, Sang Eun, et al.
Publicado: (2019)

An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015)

Human germ cell tumours: expression of γ-glutamyl transpeptidase and sensitivity to cisplatin
por: Hanigan, M H, et al.
Publicado: (1999)

Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine
por: Nocera, M, et al.
Publicado: (2000)

Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
por: Fosså, S D, et al.
Publicado: (1999)

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
por: Turner, N C, et al.
Publicado: (2010)

Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin
por: Johanson, V, et al.
Publicado: (1999)

Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours
por: Anthoney, D A, et al.
Publicado: (2004)

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
por: Kovacs, M S, et al.
Publicado: (1999)

Recurrent Metastatic Choriocarcinoma Responsive to Etoposide and Cisplatin with Etoposide, Methotrexate, and Dactinomycin: A Case Report
por: Das, Sunil Kumar, et al.
Publicado: (2022)

Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.
por: Kok, T. C., et al.
Publicado: (1996)

Emergency Etoposide-Cisplatin (Em-EP) for patients with germ cell tumours (GCT) and trophoblastic neoplasia (TN)
por: Chan Wah Hak, Charleen, et al.
Publicado: (2019)

A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts
por: Pratesi, G, et al.
Publicado: (1999)

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial
por: Morizane, Chigusa, et al.
Publicado: (2022)

Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines
por: Busch, Maike, et al.
Publicado: (2018)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

Hepatocellular carcinoma
por: Giovannini, M, et al.
Publicado: (2001)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin
por: Meczes, E L, et al.
Publicado: (2002)

Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia
por: Aminimoghaddam, Soheila, et al.
Publicado: (2018)

Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis
por: Puliafito, Ivana, et al.
Publicado: (2023)

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
por: Freyer, G, et al.
Publicado: (2000)

Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis
por: Schlippe, M von, et al.
Publicado: (2001)

PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line
por: Lai, Zih-Yin, et al.
Publicado: (2017)

Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site
por: Piga, A, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_bfjjlqfk2eulhp2fcpp3flast3